

FUCHS HENRY J  
Form 4  
January 04, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
FUCHS HENRY J

2. Issuer Name and Ticker or Trading Symbol  
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
01/02/2018

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
President, Worldwide R&D

C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST.

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting Person

SAN RAFAEL, CA 94901

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price                                      |
| Common Stock                    | 01/02/2018 <sup>(1)</sup>            | 01/02/2018   | M                              |   | 5,000   | A  | \$ 26.49                                   |
| Common Stock                    | 01/02/2018 <sup>(1)</sup>            | 01/02/2018   | M                              |   | 10,000  | A  | \$ 37.46                                   |
| Common Stock                    | 01/02/2018 <sup>(1)</sup>            | 01/02/2018   | S                              |   | 15,000  | D  | \$ 89.2267 <sup>(3)</sup>                  |
|                                 |                                      |  |                                |   |   |  | 138,976 <sup>(2)</sup>                     |
|                                 |                                      |  |                                |   |   |  | 148,976                                    |
|                                 |                                      |  |                                |   |   |  | 133,976                                    |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |        |                            |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--------|----------------------------|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title  | Amount or Number of Shares |
| Stock Option (right to buy Common Stock)   | \$ 26.49   | 01/02/2018 <sup>(1)</sup>            | 01/02/2018   | M                              | 5,000   | 11/12/2011 05/11/2021                                    | Common Stock  | 5,000  |                            |
| Stock Option (right to buy Common Stock)   | \$ 37.46   | 01/02/2018 <sup>(1)</sup>            | 01/02/2018   | M                              | 10,000  | 11/08/2012 05/07/2022                                    | Common Stock  | 10,000 |                            |

## Reporting Owners

### Reporting Owner Name / Address

### Relationships

Director 10% Owner Officer Other

FUCHS HENRY J  
C/O BIOMARIN PHARMACEUTICAL INC.  
770 LINDARO ST.  
SAN RAFAEL, CA 94901

President, Worldwide R&D

## Signatures

/s/ Laura Randall Woodhead,  
Attorney-in-Fact

01/04/2018

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Trade made pursuant to a 10b5-1 plan executed on May 9, 2017.

Amount of securities beneficially owned has been updated from the reporting person's prior report to: a) exclude 1,435 shares as

(2) previously reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017; and b) exclude 1,011 shares inadvertently included in prior reports based on a reconciliation with the Company's records.

The price in column 4 is the weighted average price. The price actually received ranged from \$88.84 to \$90.00. The reporting person shall

(3) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

(4) Reflects the number of options outstanding after the transactions from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.